Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingAetna PGT and Invasive Prenatal Coverage | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0358

    Invasive Prenatal Diagnosis of Genetic Diseases

    Customize your policy alerts

    Sign up for Aetna Policy 0358 alerts

    Get alerted when Policy 0358 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and investigational indications for invasive prenatal diagnostic procedures (CVS, amniocentesis, PUBS) and preimplantation genetic testing (PGT-M and PGT-A) for members covered by Aetna.

    Policy Summary
    PayerAetna
    PolicyInvasive Prenatal Diagnosis of Genetic Diseases
    Policy CodePolicy 0358
    Change TypeNo material change
    Effective DateNov 9, 1999
    Last ReviewJul 28, 2023
    Next Review DateApr 11, 2024
    Key ActionFor PGT-M, document that the test's technical and clinical performance is supported by peer-reviewed literature, the specific mutation(s) identified in the family, and that results will change management and eliminate the need for subsequent invasive prenatal diagnosis.
    SourceLink
    PGT-MPGT-M considered medically necessary
    PGT-APGT-A considered experimental/investigational
    3Invasive procedures considered necessary
    77+References listed
    1999Original effective date
    07/28/2023Last review

    Coverage Criteria

    inv-01: PGT-M medical necessity

    Covered when ALL of the following are met:

    PGT-M medical necessity: 1) Technical and clinical performance of the genetic test is supported by published peer-reviewed medical literature; and 2) PGT-M / PGD is performed for any of the following indications: (a) to diagnose an autosomal dominant condition when at least one parent is a known carrier; or (b) to diagnose an autosomal recessive condition when both parents are known carriers; or (c) to diagnose an X-linked condition when at least one parent is a known carrier (Fragile X meets criterion when one parent has >55 CGG repeats); or (d) to diagnose an embryo at risk for a disease-causing chromosomal rearrangement when one parent is a known carrier of a balanced or unbalanced chromosomal rearrangement; and 3) Results of genetic testing will directly impact and change management of the covered member; and 4) The PGT-M / PGD procedure will eliminate the need for subsequent invasive prenatal diagnosis by genetic amniocentesis or CVS; and 5) A specific mutation, or set of mutations, has been identified that specifically identifies the genetic disease with a high degree of reliability; and 6) The genetic disease is associated with clinically significant morbidity or disability.

    All listed criteria must be met

    inv-02: Invasive prenatal diagnosis

    Covered when ANY of the following apply:

    Policy Summary
    PayerAetna
    PolicyInvasive Prenatal Diagnosis of Genetic Diseases
    Policy CodePolicy 0358
    Change TypeNo material change
    Effective DateNov 9, 1999
    Last ReviewJul 28, 2023
    Next Review DateApr 11, 2024
    Key ActionFor PGT-M, document that the test's technical and clinical performance is supported by peer-reviewed literature, the specific mutation(s) identified in the family, and that results will change management and eliminate the need for subsequent invasive prenatal diagnosis.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsNot Covered / ExclusionsProvider Actions, Documentation, and Billing GuidanceCoding (CPT, HCPCS, ICD-10)Definitions and BackgroundEligibility RequirementsProvider Actions — Essentials and ConsentRevision History and References
    Invasive prenatal diagnosis by chorionic villus sampling (CVS), genetic amniocentesis, and percutaneous umbilical blood sampling (PUBS/cordocentesis) for diagnosis of fetal chromosomal abnormalities; and conventional cytogenetic analysis and QF-PCR when prenatal testing is performed solely because of increased risk of aneuploidy in chromosomes 13, 18, 21, X or Y; and both conventional cytogenetics and QF-PCR in all cases referred for fetal ultrasound abnormality (including nuchal translucency > 3.5 mm) or familial chromosomal rearrangement; and cytogenetic follow-up of QF-PCR findings of trisomy 13 and 21 to rule out inherited Robertsonian translocations.

    Any listed indication supports medical necessity

    inv-03: General coverage conclusion

    Coverage stance based on available evidence:

    Overall evidence: Current high-quality evidence is insufficient to demonstrate that PGT-A improves cumulative live-birth rates or live-birth rate after first embryo transfer; some PGT-A methods (notably FISH-based cleavage-stage PGT-A) may reduce live-births and are probably harmful. The quality of evidence ranged low-to-moderate in systematic reviews (e.g., Cochrane analyses of randomized trials).

    Evidence summaries from systematic reviews and RCTs

    inv-04: Situations with limited supportive evidence

    Subgroup evidence and potential covered scenarios:

    Potential benefit groups: Some randomized trials and observational cohorts reported improved implantation or clinical pregnancy rates in selected groups (e.g., young, good-prognosis patients) and small studies of poor-prognosis IVF patients; retrospective SNP-based PGT-A cohorts reported high implantation and live-birth rates per transfer, but these lacked randomized controls and the evidence is limited and non-randomized; clinical utility of PGT-A remains to be determined and should be considered experimental outside study settings for many indications.

    Limited and often non-randomized evidence; counseling and informed consent recommended

    PGT-M (formerly PGD) is considered medically necessary when all policy criteria are met: the test’s technical and clinical performance is supported by peer‑reviewed literature; the indication is for a defined single‑gene or parental structural rearrangement risk (autosomal dominant with ≥1 parent carrier, autosomal recessive with both parents carriers, X‑linked with ≥1 parent carrier, or embryo at risk because a parent carries a balanced/unbalanced rearrangement); results will directly change management; the PGT‑M procedure will eliminate the need for subsequent invasive prenatal diagnosis (CVS or amniocentesis); a specific mutation (or set of mutations) has been identified that reliably identifies the disease; and the condition is associated with clinically significant morbidity or disability. (Coverage requirements summarized from policy criteria.)

    PGT‑M is not medically necessary when used for non‑medical sex selection. The policy also states that using PGT‑M/PGD to evaluate fetal chromosomal abnormalities is considered investigational because PGT‑M is less accurate than cytogenetic analysis of CVS or amniocentesis. For single‑cell PCR‑based PGT‑M, intracytoplasmic sperm injection (ICSI) is recommended to avoid contamination; the embryo biopsy procedure itself is considered medically necessary only when the PGT‑M criteria are satisfied. (See policy notes on technique and IVF coordination.)

    Cleavage‑stage PGS using FISH (day‑3 blastomere biopsy with FISH‑based analysis) has not been shown to improve live‑birth rates and may be detrimental. Randomized trials and systematic reviews concluded that PGS as historically performed does not increase live births in women of advanced maternal age, previous implantation failure, or recurrent pregnancy loss, and evidence does not support routine use of FISH‑based cleavage‑stage PGS to improve IVF outcomes.

    Professional society reviews and meta‑analyses cited in the policy indicate that day‑3 blastomere biopsy with FISH decreases the chance of live birth and therefore is not recommended as routine care for advanced maternal age or prior implantation failure. Where new methods (blastocyst biopsy with comprehensive chromosome testing) are evaluated, the policy emphasizes the need for rigorous evidence before adoption.

    The policy concludes that PGT‑A performed with first‑generation cleavage‑stage FISH is probably harmful and is not supported by the evidence. Meta‑analyses of randomized trials that used cleavage‑stage biopsy with FISH reported lower live‑birth and ongoing pregnancy rates compared with standard IVF, leading to the assessment that this modality is detrimental rather than beneficial.

    Because of technical limitations (testing a single blastomere, mosaicism, and FISH’s limited chromosome coverage), first‑generation FISH‑based PGT‑A is specifically identified as an approach that should not be used routinely.

    The policy states that use of FISH for genetic analysis in PGT‑A is probably harmful and should not be performed routinely. Systematic reviews and randomized trials report reductions in pregnancy and live‑birth outcomes with FISH‑based approaches, and technical drawbacks (including mosaicism and limitations in probe coverage) underlie these unfavorable results.

    Newer forms of PGT‑A (e.g., blastocyst‑stage biopsy with genome‑wide methods) remain unproven for routine use and, as discussed in the policy, should be evaluated in controlled study settings before broad clinical adoption.

    This Clinical Policy Bulletin provides a general description of plan benefits and evidence‑based coverage positions; it does not constitute a contract. Specific plan exclusions, coverage limits, and benefit determinations are governed by the member’s benefit plan documents and applicable contract provisions rather than the bulletin itself.

    Readers should also note that certain laboratory‑specific assays are discussed as investigational in the policy (see investigational list) and plan‑level applicability may vary according to benefit design and adjudication rules.

    PGT‑A (formerly PGS), invasive prenatal screening for variants of uncertain significance (VUS), and PGT‑M performed to evaluate a VUS or using multigene panels at the time of PGT‑M are considered investigational or not medically necessary. The policy lists PGT‑A/PGS and use of PGT for VUS detection or routine multigene panels at embryo testing among interventions that lack sufficient evidence of clinical utility and may be denied coverage.

    Specific named commercial assays (examples cited elsewhere in the policy) are evaluated on the basis of published peer‑reviewed performance data; assays without such evidence are noted as not supported.

    Randomized trial data and evidence syntheses indicate that PGS using day‑3 blastomere biopsy with FISH decreases live‑birth rates and therefore is not recommended for women of advanced maternal age or those with prior implantation failure. The policy recommends against routine use of day‑3 cleavage‑stage biopsy with FISH for these higher‑risk groups based on trials showing worse outcomes compared with standard IVF.

    Where alternative biopsy timing (blastocyst-stage) and comprehensive chromosome testing have been studied, the evidence is limited and inconclusive, and the policy cautions that such newer approaches should be validated in randomized settings before routine clinical use.

    Overall, routine use of PGT‑A as currently performed is unsupported by high‑quality evidence and is considered not appropriate for broad clinical application. Meta‑analyses and Cochrane‑style reviews found insufficient evidence that PGT‑A increases cumulative live‑birth rates or live‑birth rates after the first embryo transfer, and in some analyses PGT‑A was associated with reductions in ongoing pregnancy and clinical pregnancy rates.

    The policy therefore characterizes routine PGT‑A as lacking established clinical utility and notes that PGT‑A using FISH is probably harmful.

    Evidence is insufficient to support routine clinical use of PGT‑A: randomized trials, systematic reviews, and meta‑analyses demonstrate low‑to‑moderate quality evidence with inconsistent findings and potential harm with some modalities. The policy emphasizes that clinical utility of PGT‑A remains unestablished, that false‑positive/false‑negative and mosaic results are possible, and that traditional diagnostic testing should still be offered to patients who have had PGT‑A.

    Given these limitations, PGT‑A for routine IVF or for broad patient populations is considered investigational pending higher‑quality evidence from randomized trials showing net clinical benefit.

    Covered Indications

    inv-51: Diagnosis of specific single-gene disorders (PGT-M) when parental carrier status demonstrated

    Must meet all PGT-M criteria:

    Diagnosis of single-gene disorders (PGT-M): Coverage is limited to embryos at risk for an established monogenic disorder when parental carrier status for the specific mutation(s) has been demonstrated (e.g., autosomal recessive: both parents carriers; autosomal dominant: at least one parent carrier; X-linked: at least one parent carrier). Documentation must demonstrate the identified mutation(s), peer-reviewed support for the test methodology, that results will change management, and that PGT-M will obviate the need for subsequent invasive prenatal diagnosis.

    All listed criteria must be documented

    inv-52: Invasive prenatal diagnostic testing (CVS, amniocentesis, PUBS) for fetal chromosomal abnormalities and when ultrasound abnormalities or familial chromosomal rearrangement are present

    Invasive prenatal diagnostic testing: Chorionic villus sampling (CVS), genetic amniocentesis, and PUBS (cordocentesis) are medically necessary for diagnosis of fetal chromosomal abnormalities and are indicated when ultrasound abnormalities are present or when a familial chromosomal rearrangement has been identified in a parent. Appropriate laboratory testing includes conventional cytogenetics, QF-PCR, karyotype, FISH, or molecular genetic testing as clinically indicated, with documentation of specimen type and test performed.

    Indications and specimen/test documentation required

    inv-53: Translocation carriers

    Translocation carriers: PGD/PGT-SR has been applied successfully for parental translocation carriers to reduce spontaneous abortions and improve chances of viable pregnancy; once a parental translocation is identified (karyotype), PGD may be offered to select chromosomally balanced/euploid embryos. Success is related to baseline rates of unbalanced gametes and laboratory methods validated for single-cell analysis.

    Parental karyotype must document translocation

    inv-54: Sex-linked single-gene disorders

    Sex-linked single-gene disorders: PGD/PGT-M using PCR or FISH-based methods can be used to prevent transmission of X-linked conditions (eg, hemophilia) by sexing embryos or detecting the causative mutation when a parent is a known carrier; methods must be validated and carrier status documented.

    Carrier status must be documented; ICSI recommended for PCR-based single-cell testing to avoid contamination

    inv-55: IVF in poor-prognosis patients or couples with recurrent pregnancy loss carrying structural chromosomal rearrangements may be considered for IVF-PGT in select cases under study conditions

    IVF-PGT in recurrent pregnancy loss / poor prognosis: IVF with PGT (including PGD for structural rearrangements) may be considered in select poor-prognosis patients or couples with recurrent pregnancy loss who carry structural chromosomal rearrangements, but evidence is limited; such use is best performed under study conditions with informed consent and counseling, and IVF-PGD should not be first-line for RPL with structural rearrangement.

    Offer under study conditions; counsel regarding alternatives including natural conception

    inv-56: PGT-M and PGT-SR for established monogenic disorders or parental structural rearrangements

    Established clinical use: Preimplantation genetic testing–monogenic (PGT-M) and preimplantation genetic testing–structural rearrangements (PGT-SR) are clinically established for testing embryos at risk because of known parental monogenic disorders or structural chromosomal rearrangements; laboratory methods and validation should be supported by peer-reviewed literature.

    Clinical use of PGT-M and PGT-SR is described as firmly established

    Not Covered / Exclusions

    The policy lists as not covered interventions including: PGT‑A/PGS generally; testing intended to detect variants of uncertain significance (VUS); use of multigene panels at the time of PGT‑M; HLA determination via PGT for donor‑suitability purposes; and specific commercial assays for which peer‑reviewed evidence of technical and clinical performance is lacking.

    These exclusions reflect the policy’s stance that such uses are experimental/investigational or lack demonstrated clinical utility and therefore are not routinely reimbursed.

    Routine FISH‑based cleavage‑stage PGS is identified as not supported to improve live‑birth rates and may be ineffective or potentially harmful. The policy references randomized trials and meta‑analyses showing lower ongoing pregnancy and live‑birth rates with cleavage‑stage FISH‑based PGS compared with standard IVF, and therefore excludes routine coverage for this modality.

    The policy recommends that newer array‑based or blastocyst‑stage approaches be studied rigorously before routine adoption, and that FISH‑based cleavage‑stage PGS should not be offered as standard care.

    Routine PGT‑A as currently performed—particularly FISH‑based cleavage‑stage methods—is unsupported by sufficient good‑quality evidence and may be excluded from routine coverage. Meta‑analytic data cited in the policy indicate possible reductions in clinical and ongoing pregnancies with PGT‑A in some trials, underpinning the not‑covered stance for routine use.

    The policy stresses that until robust evidence demonstrates improved cumulative live‑birth outcomes, routine PGT‑A will not be considered a covered, standard addition to IVF.

    The policy explicitly states that offering PGT‑A as a routine addition to IVF is not supported by sufficient evidence; first‑generation (FISH‑based) PGT‑A is described as probably harmful. As a result, routine incorporation of PGT‑A into IVF cycles is not covered and may be denied when submitted as a standard, non‑research intervention.

    Newer PGT‑A approaches (blastocyst biopsy with genome‑wide testing) remain investigational and, per the policy, should be offered only under study conditions with informed consent.

    Provider Actions, Documentation, and Billing Guidance

    Note

    Coverage Tied to Policy Criteria

    CPT/HCPCS codes listed in this policy are covered only when the member and clinical situation meet the medical necessity criteria described in the policy (e.g., indications and all required supporting criteria for PGT‑M, and indications for invasive prenatal diagnosis such as CVS, amniocentesis, or PUBS).

    • Affected codes include, but are not limited to: 59000, 59012, 59015, 81171-81244, 88248, 88271-88299, 89290-89291 (see policy code list).
    Denial Risk

    Evidence and Study‑Condition Requirement

    Some procedures (notably PGT‑A/PGS and novel or laboratory‑specific comprehensive embryonic assays) are considered experimental/investigational or supported only in research/study settings until sufficient high‑quality evidence demonstrates clinical benefit. When evidence is limited or conflicting (for example, PGT‑A with genome‑wide methods, blastocyst biopsy algorithms, or new commercial laboratory assays), use should be limited to study conditions with appropriate informed consent.

    • Randomized trials and systematic reviews have not established clear improvement in live‑birth rates with routine PGT‑A; some PGT‑A approaches (eg, FISH‑based PGS) may be harmful.
    • Newer blastocyst biopsy plus comprehensive testing strategies are regarded as investigational until validated by intent‑to‑treat clinical trials.
    Prior Authorization

    Potential Prior Authorization for Specific PGT Assays

    Certain laboratory assays and comprehensive PGT tests (including some proprietary PGT‑A or PGT‑M platforms) may require payer review or pre‑authorization prior to coverage; check plan benefits and medical policy for specific prior authorization procedures.

    • Examples: multi‑SNP microarray or whole‑genome embryonic assays (see code list: 0254U, 0396U) may be subject to review.
    • IVF procedure coverage is limited to members with ART benefits who meet IVF medical necessity criteria per CPB 0327.
    Denial Risk

    Experimental/Investigational — Potential Denial Trigger

    The policy explicitly identifies PGT‑A (preimplantation genetic testing for aneuploidy/PGS) and certain newer PGT approaches as experimental/investigational; such procedures are not covered because evidence is insufficient to demonstrate improved clinical outcomes and may pose harm in routine practice.

    • Procedures to detect variants of uncertain significance (VUS) or routine PGT‑A for IVF outcome optimization are considered experimental/investigational and may be denied.
    • FISH‑based PGT‑A/PGS is noted as probably harmful and not supported for routine use.
    Note

    Prior Authorization / Step Therapy — None Stated in This Excerpt

    No additional explicit prior authorization workflow or uniform step‑therapy requirement is stated in this excerpt; review the member's benefit plan and payer procedures for any local authorization rules.

    • The excerpt does not state a generic step‑therapy or quantity‑limit requirement for invasive prenatal diagnostic tests or PGT‑M.
    • If IVF/ART services are requested, plan ART/IVF benefit eligibility must be confirmed (CPB 0327).
    Documentation Required

    Insemination and Testing Documentation

    For PCR‑based single‑cell diagnostics (PGT‑M), ICSI is recommended to minimize contamination risk from non‑fertilizing sperm; laboratory methods and insemination technique should be documented when PCR or other sensitive molecular assays are used.

    • Document method of insemination (ICSI vs conventional) when PGT‑M/PCR testing is performed.
    • Use of ICSI is medically necessary for carriers of single‑gene disorders when PCR will be applied to avoid contamination.
    Documentation Required

    Specimen and Test Documentation

    Providers should document specimen type and the specific test performed for prenatal diagnostic procedures (eg, CVS, amniocentesis, PUBS) and for PGT procedures (eg, blastomere, polar body, trophectoderm biopsy), including laboratory method (karyotype, QF‑PCR, FISH, array‑CGH, SNP array, targeted molecular assay) and the specific mutations/targets evaluated for PGT‑M.

    • Record specimen source (amniotic fluid, chorionic villi, cord blood, embryo cell type) and assay used.
    • For PGT‑M, document the specific mutation(s) identified in the parents that the assay targets and published evidence supporting technical/clinical performance.
    Documentation Required

    Counseling and Documentation

    Counsel patients that a normal or negative preimplantation genetic test or prenatal screening result does not guarantee a newborn without genetic abnormalities; offer traditional diagnostic testing or screening in pregnancy following PGT‑A or PGT‑M per professional guidance and obtain informed consent when tests are investigational or performed under study conditions.

    • Document that counseling occurred regarding limitations of PGT (false positives, false negatives, mosaicism) and the recommendation for confirmatory diagnostic testing as indicated.
    • Obtain and document informed consent when PGT‑A or novel PGT approaches are offered under research or investigational frameworks.
    Note

    Consider Non‑PGT‑A Options First

    Consider non‑PGT‑A options and discuss alternatives (including traditional diagnostic prenatal testing and the established use of PGT‑M for single‑gene disorders) before selecting IVF with PGT‑A; ensure patients understand the current evidence limits and alternative pathways to manage reproductive risk.

    • Discuss alternatives such as invasive prenatal diagnosis (CVS, amniocentesis) when clinically indicated.
    • Coordinate PGT‑M with reproductive specialists and document decision‑making rationale in the medical record.

    Coding (CPT, HCPCS, ICD-10)

    Covered CPT Codes if criteria metCPTCovered
    59000Amniocentesis; diagnostic.
    59012Cordocentesis (intrauterine), any method.
    59015Chorionic villus sampling, any method.
    81171AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles.
    81172AFF2 (AF4/FMR2 family, member 2 [FMR2]) (eg, fragile X mental retardation 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status).
    81243FMR1 (Fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; evaluation to detect abnormal (eg, expanded) alleles.
    81244FMR1 (fragile X mental retardation 1) (eg, fragile X mental retardation) gene analysis; characterization of alleles (eg, expanded size and promoter methylation status).
    88248Chromosome analysis for breakage syndromes; baseline breakage, score 50-100 cells, count 20 cells, 2 karyotypes (eg, for ataxia telangiectasia, Fanconi anemia, fragile X).
    88271-88299Molecular cytogenetics.
    89290-89291Biopsy, oocyte polar body or embryo blastomere, microtechnique (for pre-implantation genetic diagnosis); less than, equal, or greater than 5 embryos [not covered to enhance delivery rates in advanced reproductive technologies].
    CPT codes not covered / problematic assaysCPTNot Covered
    0254UReproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy, per embryo tested.
    0396UObstetrics (pre-implantation genetic testing), evaluation of 300000 DNA single-nucleotide polymorphisms (SNPs) by microarray, embryonic tissue, algorithm reported as a probability for single-gene germline conditions.
    86828-86835Antibody to human leukocyte antigens (HLA) assays.
    Other related CPT codesCPT
    58321-58322Artificial insemination.
    81228-81229Cytogenomic constitutional (genome-wide) microarray analysis.
    HCPCS related codesHCPCS
    S3840DNA analysis for germline mutations of the RET proto-oncogene for susceptibility to multiple endocrine neoplasia type 2.
    S3841-S3853Genetic testing.
    S4011-S4022In vitro fertilization.
    ICD-10 codes covered / not coveredICD-10
    Q90.0-Q90.9Down syndrome.
    Q91.0-Q91.3Trisomy 18 [Edward's syndrome].
    Q91.4-Q91.7Trisomy 13 [Patau's syndrome].
    Q99.2Fragile X chromosome.
    Z14.1Cystic fibrosis carrier.
    N96Recurrent pregnancy loss.
    Q99.8Other specified chromosome abnormalities [not covered for VUS (unclassified variant or variant of uncertain significance)].
    Q99.9Chromosomal abnormality, unspecified [not covered for VUS (unclassified variant or variant of uncertain significance)].
    No CPT/ICD codes listed in this excerptmixed
    No codes listed
    Fragile X repeat thresholds (PGT-M context)
    Fragile X premutation threshold>55 CGG triplet repeats (premutation range referenced as indication for PGT-M consideration)
    Full mutation for Fragile X (diagnostic)>200 CGG repeats with abnormal methylation (full-mutation) establishes diagnosis of Fragile X syndrome
    Clinical relevance statedPGT-M may be considered when the mother is a known carrier of Fragile X premutation/full mutation and testing would eliminate need for invasive prenatal diagnosis

    Definitions and Background

    PGT‑M (preimplantation genetic testing for monogenic disorders) detects specific single‑gene disorders by molecular analysis of single embryonic cells and is medically necessary when the policy’s strict criteria are satisfied. The procedure is intended to identify embryos unaffected by a known familial mutation so that affected embryos are not transferred, thereby eliminating the need for later invasive prenatal diagnosis when criteria are met.

    For conditions such as cystic fibrosis or fragile X (with parental premutation defined in the policy as >55 triplet repeats for Fragile X carrier status), PGT‑M is an established clinical application when parental carrier status and the causative mutation(s) have been documented.

    PGT-M (preimplantation genetic testing for monogenic disorders)
    DefinitionPreimplantation genetic testing for monogenic disorders (PGT-M), formerly called preimplantation genetic diagnosis (PGD), is testing of embryos produced by IVF to detect specific single-gene disorders prior to uterine transfer.
    IndicationUsed when one or both parents carry a gene mutation or a balanced chromosomal rearrangement and testing will identify embryos without the familial mutation or unbalanced complement.
    SpecimenCell(s) are removed from embryos under microscopic guidance and analyzed for presence/absence of the specific mutation(s) prior to implantation.
    PGT-A / PGS
    DefinitionPreimplantation genetic testing for aneuploidy (PGT-A), formerly called preimplantation genetic screening (PGS), is a broad screening test performed on embryos after IVF to assess chromosome number abnormalities (aneuploidy) across all chromosomes.
    PurposeProposed for individuals at increased risk of aneuploid embryos (e.g., advanced maternal age, recurrent pregnancy loss, repeated IVF failure) to screen embryos prior to transfer.
    LimitationsThe clinical utility and best use of PGT-A remain to be determined; false-positive/false-negative results and mosaicism are recognized limitations.
    PGD (preimplantation genetic diagnosis)
    DefinitionPreimplantation genetic diagnosis (PGD) is the historical term for genetic testing of embryos—now commonly referred to as PGT-M when targeted to single-gene disorders—to determine whether a familial mutation or unbalanced chromosomal complement has been transmitted prior to uterine transfer.
    ContextPGD/PGT-M is performed on embryos following IVF; unaffected embryos may be selected for implantation to prevent transmission of specific genetic diseases.
    Terminology notePGD is the predecessor term; current nomenclature distinguishes PGT-M (monogenic) and PGT-A (aneuploidy).
    PGS (historical FISH-based cleavage-stage description)
    Historical PGS descriptionPreimplantation genetic screening (PGS) historically involved FISH-based analysis of cleavage-stage (day 3) blastomeres to screen a limited set of chromosomes.
    Evidence noteMultiple RCTs using FISH-based cleavage-stage PGS showed no increase in delivery rates; day-3 blastomere biopsy with FISH is associated with decreased live-birth chances in some settings.
    EvolutionArray-based methods (aCGH, SNP arrays) and blastocyst-stage trophectoderm biopsy have been proposed to address limitations of early FISH-based PGS.
    Prenatal invasive diagnostic genetic tests (CVS, amnio, PUBS)
    DefinitionPrenatal invasive diagnostic genetic tests include chorionic villus sampling (CVS), genetic amniocentesis, and percutaneous umbilical blood sampling (PUBS) performed during pregnancy to diagnose fetal chromosomal or genetic abnormalities.
    SpecimensTesting may be performed on amniotic fluid, chorionic villi, or percutaneous umbilical blood samples.
    MethodsLaboratory methods include chromosome analysis (karyotype), fluorescence in situ hybridization (FISH), and molecular genetic testing on fetal cells obtained by CVS or amniocentesis.
    SMART PGT-A (24-chromosome analysis with mosaicism and mtDNA score)
    DescriptionSMART PGT-A analyzes all 24 chromosomes using embryonic DNA genomic sequence analysis and reports euploidy, monosomy, trisomy, mosaicism, segmental aneuploidy and provides a mitochondrial DNA (mtDNA) score.
    ReportingResults are reported per embryo as normal (euploid), monosomy, trisomy, partial deletions/duplications, mosaicism, and segmental aneuploidy.
    Guidance noteProfessional societies note that the value of PGT-A as a screening test remains to be determined and caution interpretation especially for mosaic results.
    PGT-A (broad screening for all chromosomes)
    DefinitionPGT-A is a broad screening test that assesses all chromosomes (the 22 autosome pairs and sex chromosomes) in embryos to detect aneuploidy prior to embryo transfer.
    ScopeAnalytic platforms include aCGH, SNP arrays, and NGS-based methods to evaluate the entire chromosome complement.
    LimitationFalse-positive/false-negative results and mosaicism are recognized; a normal PGT-A result does not guarantee a newborn without genetic abnormalities.
    PGT-M (targeted testing for inherited single-gene disorders)
    DefinitionPGT-M is preimplantation genetic testing targeted to inherited single-gene (monogenic) disorders; it identifies embryos that do or do not carry the familial pathogenic variant(s) prior to transfer.
    ApplicationsUsed for autosomal dominant, autosomal recessive, and X-linked single-gene disorders when specific familial mutation(s) have been identified in parents.
    Method notePGT-M employs molecular single-cell techniques (e.g., PCR, SNP-based approaches) on embryo biopsy samples and requires identification of the specific mutation(s) to be tested.
    PGT-SR (structural rearrangements)
    DefinitionPreimplantation genetic testing for structural rearrangements (PGT-SR) evaluates embryos at risk because a parent carries a structural chromosomal abnormality (e.g., translocation, inversion, deletion) to identify embryos with balanced or unbalanced complements.
    IndicationApplied to parental translocation carriers to help achieve viable pregnancies and reduce spontaneous abortions by selecting embryos without unbalanced rearrangements.
    Testing approachTypically uses cytogenetic or comprehensive chromosome analysis (array or sequencing-based) on embryo biopsy samples to detect structural imbalances.

    Eligibility Requirements

    The policy does not list additional standalone eligibility requirements in separate sections beyond the PGT‑M criteria themselves. Coverage for PGT‑M is tied to demonstration of parental carrier status or documented familial mutation(s) and to meeting the listed medical‑necessity criteria; other eligibility nodes (such as age or prior treatments) are not specified as independent top‑level requirements in this excerpt.

    For invasive prenatal diagnostic procedures (CVS, amniocentesis, PUBS) coverage is described by clinical indications (e.g., fetal ultrasound abnormality, increased nuchal translucency >3.5 mm, or familial chromosomal rearrangement) rather than by separate eligibility checklists.

    The policy’s eligibility expectations are embodied in the PGT‑M medical necessity criteria: identification of a specific mutation or parental carrier status is required, and the test must be expected to change management and obviate invasive prenatal diagnosis. No additional eligibility elements (such as explicit age cutoffs or prior authorization prerequisites) are defined as separate top‑level nodes in this excerpt.

    Providers should ensure documentation demonstrates how the case meets each PGT‑M criterion before submission for coverage adjudication.

    This section does not specify extra eligibility criteria beyond the core policy statements. Instead, the policy focuses on clinical indications and evidence‑based justification for PGT‑M and invasive prenatal diagnostic testing, leaving plan‑specific benefit limits and any administrative eligibility rules to the member’s benefit documents.

    When considering PGT‑A (investigational/not covered for routine use) or other investigational applications, providers should be aware that eligibility for coverage is unlikely absent participation in approved research or explicit plan provisions allowing such services.

    The policy references parental carrier identification as the primary prerequisite for PGT‑M: for autosomal recessive disorders both parents must be carriers; for autosomal dominant and X‑linked disorders at least one parent must be a carrier. Identification of a known familial structural rearrangement (translocation) is likewise required before offering PGD for structural rearrangements.

    These family‑history and diagnostic prerequisites are the operative eligibility requirements for PGT‑M coverage in this policy excerpt.

    The policy does not enumerate additional administrative eligibility nodes in this excerpt. It emphasizes that PGT‑A, multigene panels at time of PGT‑M, and testing for VUS are investigational and not covered, reinforcing that eligibility for those services is not present under routine coverage.

    Clinicians should use the policy’s clinical criteria (documented mutation/carrier status and expected change in management) as the basis for determining whether the member meets coverage conditions for PGT‑M.

    No separate top‑level eligibility nodes (e.g., specific age or prior trial requirements) are provided in this excerpt beyond the PGT‑M clinical criteria and the listed clinical indications for invasive prenatal diagnosis. The policy ties coverage decisions to clinical evidence and individualized demonstration that PGT‑M will change management and eliminate invasive testing.

    Providers should document parental testing and mutation identification as part of eligibility assessment for PGT‑M claims.

    The policy does not specify additional eligibility components in this fragment; rather, coverage is decisioned on meeting the explicit medical‑necessity criteria and the presence of documented familial genetic findings. Newer PGT‑A approaches remain investigational and are not covered routinely, independent of additional eligibility features.

    Where investigational procedures are proposed, the policy suggests they may be appropriate only within properly conducted research protocols with informed consent.

    Eligibility for PGT‑M coverage is predicated on demonstration of known parental carrier status or a specific familial mutation and meeting each of the medical‑necessity criteria (test performance evidence; impact on management; elimination of invasive testing; identification of the causative mutation; and association with significant morbidity). The policy does not enumerate additional administrative eligibility nodes in this excerpt.

    Providers should ensure the clinical record documents the mutation(s) identified in the family and explains how PGT‑M results will directly alter management to support coverage.

    Provider Actions — Essentials and Consent

    Documentation Required

    Document parental carrier status and genetic context for PGT-M

    When PGT-M is requested, providers must document parental carrier status and appropriate genetic context demonstrating that one or both parents carry the causative mutation(s) for the indicated monogenic disorder.

    • Document parental genetic testing confirming carrier status (e.g., both parents for autosomal recessive, at least one for autosomal dominant or X-linked).
    • For Fragile X, document that one parent is a known carrier with >55 CGG repeats when applicable.
    Documentation Required

    Obtain and document informed consent and counseling when offering study-condition PGT

    When PGT-M or experimental PGT approaches are offered under study conditions, the policy implies appropriate informed consent and counseling are required prior to offering the procedure.

    • Ensure that informed consent for research/experimental PGT methods is obtained and documented.
    • Document counseling about experimental status, uncertain benefit, and risks.
    Documentation Required

    Document informed consent/counseling for research-condition PGT

    When experimental or research-condition PGT approaches are used, providers should ensure appropriate informed consent and counseling are in the medical record, as implied by the policy.

    • Document that the patient was informed about the investigational nature of the procedure and potential alternatives.
    • Record consent specific to the study-condition offering.
    Documentation Required

    Document counseling and consent when offering PGT under study/research conditions

    Providers offering PGT under study conditions should document informed consent and counseling addressing uncertain effectiveness, potential harms, and alternatives, as implied across policy recommendations.

    • Record counseling on limitations of PGT-A and the expectation to offer traditional diagnostic testing post‑PGT-A.
    • Include discussion of mosaicism and potential for false results.
    Note

    Coordinate PGT-M procedures with IVF program and document logistics

    Policy notes coordination with IVF programs is required for PGT-M performed on embryos produced after IVF; arrange logistics with the IVF program and document coordination.

    • Verify and document that embryos were produced via IVF before PGT-M biopsy.
    • Coordinate scheduling and lab workflow with the IVF program and document communications.

    Revision History and References

    The policy cites a broad literature base including multiple randomized trials, meta‑analyses, and systematic reviews assessing PGT‑A/PGS and PGT‑M. For PGT‑A, Cochrane‑style reviews and meta‑analyses (summarized across 13 trials/2,794 women in some reviews and 5 RCTs in specific analyses) report low‑to‑moderate quality evidence with inconsistent results and possible reductions in ongoing pregnancy or live‑birth rates for some modalities.

    Randomized trials and meta‑analyses (e.g., Mastenbroek et al., Checa et al.) underpin the policy’s conclusions that FISH‑based cleavage‑stage PGS reduced live births in some studies and that evidence for newer genome‑wide PGT‑A approaches is currently insufficient. The references list in the policy includes 70+ citations supporting these evidence summaries.